Combination of the low anticoagulant heparin CX-01 with chemotherapy for the treatment of acute myeloid leukemia
Authors:
Open Access
- 21 February 2018
- journal article
- research article
- Published by American Society of Hematology in Blood Advances
- Vol. 2 (4) , 381-389
Abstract
Key Points: In a pilot study, the nonanticoagulant heparin derivative CX-01 was well tolerated when combined with chemotherapy for the treatment of AML. Preliminary results show encouraging complete remission rates and rapid platelet recovery.Keywords
This publication has 41 references indexed in Scilit:
- CXCR4 downregulation of let-7a drives chemoresistance in acute myeloid leukemiaJournal of Clinical Investigation, 2013
- Long-term follow up of patients proceeding to transplant using plerixafor mobilized stem cells and incidence of secondary myelodysplastic syndrome/AMLBone Marrow Transplantation, 2013
- Heparin Oligosaccharides Inhibit Chemokine (CXC Motif) Ligand 12 (CXCL12) Cardioprotection by Binding Orthogonal to the Dimerization Interface, Promoting Oligomerization, and Competing with the Chemokine (CXC Motif) Receptor 4 (CXCR4) N TerminusJournal of Biological Chemistry, 2013
- A phase 1/2 study of chemosensitization with the CXCR4 antagonist plerixafor in relapsed or refractory acute myeloid leukemiaBlood, 2012
- Heparin-induced Leukocytosis Requires 6-O-Sulfation and Is Caused by Blockade of Selectin- and CXCL12 Protein-mediated Leukocyte Trafficking in MiceJournal of Biological Chemistry, 2012
- Molecular mechanisms underlying adhesion and migration of hematopoietic stem cellsCell Adhesion & Migration, 2012
- Targeting the leukemia microenvironment by CXCR4 inhibition overcomes resistance to kinase inhibitors and chemotherapy in AMLBlood, 2009
- A single dose of pegfilgrastim compared with daily filgrastim for supporting neutrophil recovery in patients treated for low-to-intermediate risk acute myeloid leukemia: results from a randomized, double-blind, phase 2 trialBMC Cancer, 2008
- Platelet factor 4 is a negative autocrine in vivo regulator of megakaryopoiesis: clinical and therapeutic implicationsBlood, 2007
- Revised Recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid LeukemiaJournal of Clinical Oncology, 2003